Is the Current Approach to Reviewing New Drugs Condemning the Victims of Rare Diseases to Death? A Call for a National Orphan Drug Review Policy

CMAJ - Canada
doi 10.1503/cmaj.050706
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Joule Inc.

Related search

A Call to Study Orphan Diseases

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Nuclear MedicineRadiologyOral SurgeryImagingDentistryForensic MedicinePathologySurgery
2018English

A Proposed Definition of Rare Diseases for China: From the Perspective of Return on Investment in New Orphan Drugs

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2015English

Rare Diseases, Drug Development, and AIDS: The Impact of the Orphan Drug Act

Milbank Quarterly
Health PolicyPublic HealthOccupational HealthEnvironmental
1995English

An Integrative, Translational Approach to Understanding Rare and Orphan Genetically Based Diseases

Interface Focus
BiochemistryBiophysicsBiomaterialsBioengineeringBiotechnologyBiomedical Engineering
2013English

Psy158 - A Pragmatic Literature Review to Identify Economic Outcomes for Repurposed Drugs in Rare Diseases

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering—A Cross-Sectional Analysis

Oncologist
Cancer ResearchMedicineOncology
2016English

First International South Caucasian Conference on Rare Diseases and Orphan Drugs

European Journal of Pediatrics
Child HealthPediatricsPerinatology
2010English

New Problems of a New Health System: The Creation of a National Public Policy of Rare Diseases Care in Brazil (1990s-2010s)

Salud Colectiva
Health PolicyPublic HealthOccupational HealthEnvironmental
2020English

A New Drug to Treat Prion Diseases

Lab Animal
Animal ScienceZoologyVeterinary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy